COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
Mike Hollan
Advertisement
Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
Articles by Mike Hollan
While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
